Loading...
•
Sep 30, 2021
Eli Lilly Q3 2021 Earnings Report
Reported robust financial results driven by volume growth and key growth products, with advancements in pipeline events.
Key Takeaways
Eli Lilly reported a strong third quarter in 2021, with revenue increasing by 18% driven by a 17% increase in volume. Key growth products contributed significantly to revenue growth. The company also highlighted pipeline advancements, including regulatory submissions and positive Phase 3 readouts.
Revenue increased 18 percent, driven by volume growth of 17 percent.
Key growth products contributed 17 percentage points of revenue growth and represented approximately 58 percent of total revenue, excluding revenue from COVID-19 therapies.
Earnings per share (EPS) decreased to $1.22 on a reported basis and increased to $1.94 on a non-GAAP basis, representing 38 percent growth versus prior year.
Lilly submitted tirzepatide in type 2 diabetes and initiated a rolling submission for donanemab to the FDA for accelerated approval in early Alzheimer's disease.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Verzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
The company updated certain elements of its 2021 financial guidance on both a reported and non-GAAP basis.
Positive Outlook
- Revenue is now expected to be between $27.2 billion and $27.6 billion.
- This increase reflects additional revenue from COVID-19 antibodies and the underlying core business.
- Estimated revenue from COVID-19 antibodies is now expected to be approximately $1.3 billion.
- Earnings per share for 2021 are now expected to be in the range of $6.38 to $6.48 on a reported basis
- Earnings per share for 2021 are now expected to be in the range of $7.95 to $8.05 on a non-GAAP basis.
Challenges Ahead
- Other income (expense) for 2021 is now expected to be expense in the range of $250 million to $150 million on a reported basis
- The company's updated reported guidance reflects the impact of the charge associated with the repurchase of higher-cost debt
- The company's updated reported guidance reflects unfavorable mark-to-market adjustments on investments in equity securities in the third quarter of 2021.
- The 2021 effective tax rate is now expected to be approximately 11 percent on a reported basis
- This reflects primarily the tax impacts of the charges related to repurchase of higher-cost debt and acquired IPR&D, as well as unfavorable mark-to-market adjustments on investments in equity securities in the third quarter of 2021.